These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22944479)

  • 21. The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from Côte d'Ivoire's Drug Access Initiative.
    Diomandé FV; Bissagnéné E; Nkengasong JN; Maurice C; Monga B; Laga M; Nolan ML
    AIDS; 2003 Jul; 17 Suppl 3():S87-93. PubMed ID: 14565614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of the Treat All Policy Among Persons with HIV Infection Enrolled in Care But Not on Antiretroviral Therapy - India, May 2017-June 2018.
    Mitruka K; Bamrotiya M; Agarwal R; Parvez A; Allam RR; Sivalenka S; Deoraj P; Prasad R; Devi U; Keskar P; Acharya S; Kannan P; Ganti R; Shah M; Todmal S; Kumar P; Chava N; Rao A; Tanwar S; Nyendak M; Ellerbrock T; Holtz TH; Gupta RS
    MMWR Morb Mortal Wkly Rep; 2018 Nov; 67(47):1305-1309. PubMed ID: 31199351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe.
    Hallett TB; Gregson S; Dube S; Mapfeka ES; Mugurungi O; Garnett GP
    Sex Transm Infect; 2011 Dec; 87(7):621-8. PubMed ID: 21636615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question.
    Eholié SP; Badje A; Kouame GM; N'takpe JB; Moh R; Danel C; Anglaret X
    AIDS Res Ther; 2016; 13():27. PubMed ID: 27462361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
    Hoen E'; Berger J; Calmy A; Moon S
    J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations.
    Doherty K; Essajee S; Penazzato M; Holmes C; Resch S; Ciaranello A
    BMC Health Serv Res; 2014 May; 14():201. PubMed ID: 24885453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addressing advanced HIV disease and mortality in global HIV programming.
    Boyd AT; Oboho I; Paulin H; Ali H; Godfrey C; Date A; Sean Cavanaugh J
    AIDS Res Ther; 2020 Jul; 17(1):40. PubMed ID: 32650797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count.
    Bigna JJ; Plottel CS; Koulla-Shiro S
    Infect Dis Poverty; 2016 Sep; 5(1):85. PubMed ID: 27593965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The economics, financing and implementation of HIV treatment as prevention: what will it take to get there?
    Wilson D; Taaffe J; Fraser-Hurt N; Gorgens M
    Afr J AIDS Res; 2014; 13(2):109-19. PubMed ID: 25174628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiated HIV care in sub-Saharan Africa: a scoping review to inform antiretroviral therapy provision for stable HIV-infected individuals in Kenya.
    Hagey JM; Li X; Barr-Walker J; Penner J; Kadima J; Oyaro P; Cohen CR
    AIDS Care; 2018 Dec; 30(12):1477-1487. PubMed ID: 30037312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya.
    Kwarisiima D; Kamya MR; Owaraganise A; Mwangwa F; Byonanebye DM; Ayieko J; Plenty A; Black D; Clark TD; Nzarubara B; Snyman K; Brown L; Bukusi E; Cohen CR; Geng EH; Charlebois ED; Ruel TD; Petersen ML; Havlir D; Jain V
    J Int AIDS Soc; 2017 Jul; 20(Suppl 4):21673. PubMed ID: 28770596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries.
    Gupta S; Granich R; Date A; Lepere P; Hersh B; Gouws E; Samb B
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1149-58. PubMed ID: 25216827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world.
    Tucker T; Yeats J
    S Afr Med J; 2001 Aug; 91(8):615. PubMed ID: 11584766
    [No Abstract]   [Full Text] [Related]  

  • 39. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral therapy needs: the effect of changing global guidelines.
    Stanecki K; Daher J; Stover J; Beusenberg M; Souteyrand Y; García Calleja JM
    Sex Transm Infect; 2010 Dec; 86 Suppl 2(Suppl_2):ii62-6. PubMed ID: 21106517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.